Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630629 | 0.99 | CPB2 (0.46) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL29630356 | 0.92 | FOLH1 (0.50) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL24130548 | 0.92 | FOLH1 (0.53) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL8759318 | 0.92 | FOLH1 (0.53) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL8759327 | 0.92 | FOLH1 (0.53) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711325 | 0.91 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711738 | 0.91 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711321 | 0.91 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL1711732 | 0.91 | CPB2 (0.47) | CPB2ERAP2ERAP1LNPEPFOLH1 | |
| SCHEMBL31181199 | 0.90 | ERAP2 (0.46) | CPB2ERAP2ERAP1LNPEPOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423422-B | Proliferation method | 花王株式会社 | 2024-05-10 | — | — | CN | claimed |
| CN-116096363-A | Coronavirus proliferation method | 花王株式会社 | 2023-05-09 | — | — | CN | claimed |
| US-12622951-B2 | Urate oxidase-albumin conjugate, preparation method thereof, and use thereof | PROABTECH CO., LTD. (KR) | 2026-05-12 | — | — | US | disclosed |
| EP-4737568-A1 | NOVEL CRISPR/CAS13 SYSTEM AND USE THEREOF | Nsage Corp. (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260109956-A1 | ADENO-ASSOCIATED VIRUS VARIANT | AAVATAR THERAPEUTICS CO LTD (KR) | 2026-04-23 | — | — | US | disclosed |
| US-20260091090-A1 | URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF | PROABTECH INC (KR) | 2026-04-02 | — | — | US | disclosed |
| US-20260001938-A1 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | 3H BIO CO LTD (KR) | 2026-01-01 | — | — | US | disclosed |
| US-12479905-B2 | Peptide used for immunotherapeutics | 3H BIO. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-12480098-B1 | Adeno-associated virus variant | AAVATAR THERAPEUTICS CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| EP-4650369-A1 | FIBROSIS TREATMENT CONTAINING ICAM-1 INHIBITOR | FNCTBiotech Inc. (KR) | 2025-11-19 | — | — | EP | disclosed |
| US-20250327120-A1 | METHOD FOR PREDICTING POSSIBLE OFF-TARGETS IN GENE EDITING PROCESS | TOOLGEN INC (KR) | 2025-10-23 | — | — | US | disclosed |
| WO-2023068736-A1 | ARGININE DECARBOXYLASE VARIANT AND FUNCTIONAL POLYPEPTIDE VARIANT-ALBUMIN CONJUGATE PREPARED USING SAME | 주식회사 프로앱텍 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023048505-A1 | APN GROUP-BEARING LINKER AND FUNCTIONAL POLYPEPTIDE VARIANT-ALBUMIN CONJUGATE PREPARED USING SAME | 주식회사 프로앱텍 | 2023-03-30 | — | — | WO | disclosed |
| US-20230087676-A1 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | 3H BIO. CO., LTD. (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2023282556-A1 | URICASE-ALBUMIN CONJUGATE DERIVED FROM ARTHROBACTER GLOBIFORMIS, METHOD FOR PRODUCING SAME, AND USE THEREOF | 주식회사 프로앱텍 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023282597-A1 | CLEAVAGE-INACTIVE CAS12F1, CLEAVAGE-INACTIVE CAS12F1-BASED FUSION PROTEIN, CRISPR GENE-EDITING SYSTEM COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | 주식회사 진코어 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023277574-A1 | METHOD FOR PRODUCING URATE OXIDASE-ALBUMIN CONJUGATE USING BCN LINKER AND USE THEREOF | 주식회사 프로앱텍 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022164291-A2 | MULTIMERIC PROTEIN-ALBUMIN CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 주식회사 프로앱텍 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022065913-A1 | URICASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 주식회사 프로앱텍 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022065936-A1 | CONJUGATE OF FUNCTIONAL POLYPEPTIDE VARIANT, AND USE THEREOF | 주식회사 프로앱텍 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001938-A1 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | HBZ, IL2, GCKR | CPB2 1305/4885ERAP2 436/4885ERAP1 282/4885 |
| US-20260091090-A1 | URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF | PNPO, LOX, TTR | CPB2 1069/4885ERAP2 633/4885ERAP1 729/4885 |
| US-12479905-B2 | Peptide used for immunotherapeutics | CD4, IL2, ICOS | CPB2 193/4885ERAP2 201/4885ERAP1 68/4885 |
| US-20260109956-A1 | ADENO-ASSOCIATED VIRUS VARIANT | METTL16, UPF1, SETD1B | CPB2 997/4885ERAP2 1820/4885ERAP1 1796/4885 |
| US-12622951-B2 | Urate oxidase-albumin conjugate, preparation method thereof, and use thereof | DUOX1, ALB, AOX1 | CPB2 1998/4885ERAP2 1383/4885ERAP1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.